Cambridge-based TRIMTECH Therapeutics has signed a research collaboration and licensing option agreement with Biogen to develop small-molecule protein degraders for neurodegenerative diseases. The deal could bring TRIMTECH up to $411 million (about €373 million), plus royalties.
ADVERTISEMENT


